

SAN ANTONIO
LIVER CANCER SYMPOSIUM

DAY ONE - THURSDAY, OCTOBER 8, 2026

7:00–8:00 a.m. Registration and Breakfast

7:15–7:55 a.m. Breakfast Product Theater

8:00–8:05 a.m. WELCOME AND OPENING REMARKS

Lei Zheng, MD, PhD — Executive Director of Mays Cancer Center at UT Health San Antonio

Sukeshi Arora, MD — Mays Cancer Center at UT Health San Antonio

Danielle Fritze, MD — Mays Cancer Center at UT Health San Antonio

PLENARY SESSION

8:10–9:15 a.m. PLENARY 1
Moderator: Danielle Fritze, MD — Mays Cancer Center at UT Health San Antonio
Speaker: Ekihiro Seki, MD, PhD — Cedars-Sinai Medical Center

8:10–9:00 a.m. Evolution of Liver

9:00–9:15 a.m. Q&A

9:20–10:35 a.m.

PROGRAM A

PRECLINICAL AND TRANSLATIONAL – LIVER CANCER

Moderators:
LuZhe Sun, PhD and Peng Zhao, PhD —
UT Health San Antonio

9:20–9:35 a.m. YAP activation induces HCC by inhibiting FXR to disrupt bile acid metabolism — Yingzi Yang, PhD — Harvard University

9:35–9:50 a.m. Wei Qiu, PhD — Loyola University Chicago

9:50–10:05 a.m. Satdarshan (Paul) Singh Monga, MD — University of Pittsburgh

10:05–10:20 a.m. Xiaoli Sun, MD, PhD- UT Health San Antonio

10:20–10:35 a.m. Q & A Panel Discussion

PROGRAM B

UPDATES IN COLON AND RECTAL CANCER

Moderator: Alicia Logue, MD —
Mays Cancer Center at UT Health San Antonio

Screening GI: Douglas K. Rex, MD —
Indiana University School of Medicine

Rectal Cancer: Amy Le, MD, MPH —
UT Health San Antonio

Liver Metastases: Jonathan Cullen , MD- UT Health San Antonio

Q&A Panel Discussion

10:35-10:50 a.m.

Break, Networking & Exhibits

10:55–11:55 a.m.

PROGRAM A

HEPATOLOGY

Moderator:
Jan Petrasek, MD — UT Health San Antonio

10:55–11:10 a.m. Hepatology Updates Disparities in HCC: Nicole Rich, MD — UT Southwestern Medical Center

11:10-11:25 a.m. Fatty Liver Therapies: Mazen Nooruddin, MD — Houston Methodist Academic Medicine Associates

11:25-11:40 a.m. Up-and-Coming Fatty Liver Therapies: Eric Lawitz, MD — Texas Liver Institute

11:40-11:55 a.m. Q&A Panel Discussion

PROGRAM B

CHOLANGIOCARCINOMA

Moderator:
Milind M. Javle, MD- UT MD Anderson Houston

Resectable Surgeon: Ashton Connor, MD, PhD -Houston Methodist Department of Surgery

Therapeutics: Tannaz Armaghany, MD- Baylor College of Medicine

Radiation Oncology: Randa Tao, MD — Mayo Clinic

Q&A Panel Discussion

11:55-1:15 p.m.

Lunch Product Theater -TBD

1:20-2:15 p.m.

PROGRAM A

EPIDEMIOLOGY

Moderator:
Amelie Ramirez, DrPH, MPH — UT Health San Antonio

1:20-1:35 p.m. GLP-1 & GI Cancers: Colton Jones, MD — UT Health San Antonio

1:35–1:50 p.m. HCC/Cirrhosis/Disparities: Martin Lajous, MD, ScD- National Institute of Public Health of Mexico

1:50-2:00 p.m. Abstract 1

2:00-2:15 p.m. Q&A Panel Discussion

2:15-2:40 p.m.

Break, Networking & Exhibits

2:45- 4:00 p.m.

PROGRAM A

HCC UPDATES IN SYSTEMIC THERAPEUTICS

Moderator:
Maen Abdelrahim, MD, PhD, Pharmacy —
Houston Methodist

2:45-3:00 p.m. First-Line Therapy: Sukeshi Arora, MD — Mays Cancer Center at UT Health San Antonio

3:00-3:15 p.m. Second-Line Therapy: Julie Rowe, MD — UT Health Houston

3:15-3:30 p.m. New Therapies: Maen Abdelrahim, MD, PhD, PharmD — Houston Methodist

3:30-3:45 p.m. Abstract 1

3:45-4:00 p.m. Q&A Panel Discussion

PROGRAM B

GENETICS VS GENOMICS IN GI CANCERS

Case-Based study; Dr. Jessica Jones

Care Cancer Risk Reduction and Education Program: Jessica Trevino Jones, MD at Mays Cancer Center at UT Health San Antonio

Disparities: Marcela Mazo Canola, MD — Mays Cancer Center at UT Health San Antonio

Genomics: Adetunji Toriola, MD, PhD, Washington University in St. Louis

Abstract 1

Q&A Panel Discussion

4:00 p.m.

Day 1 Adjournment